DoD Prostate Cancer Laboratory-Clinical Transition Award

Post Date

March 20th 2012

Application Due Date

August 23rd 2012

Funding Opportunity Number

W81XWH-12-PCRP-LCTA

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

2

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $4800000

• Award Range:

  $0 - $0

Grant Description

╔ Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. ╔ For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agentуs mechanism of action. ╔ For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans. ╔ For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device. ╔ Supports research that ranges from preclinical study through cGMP production.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  CDMRP Help Desk: 301-682-5507

• Agency Mailing Address:

  CDMRP Help Desk

• Agency Email Address:

  help@cdmrp.org